Profile: MethylGene Inc. is a clinical stage, biopharmaceutical company. We focus on the discovery, development and supply of novel therapeutics for cancer. Our MGCD265 is an oral, multi-targeted kinase inhibitor targeting the c-Met, Tie-2, Ron, VEGF1, VEGF2 and VEGF3 receptor tyrosine kinases. Our MGCD0103 is an oral, isoform-selective HDAC inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies. Our MGCD290 is a fungal Hos2 inhibitor used in combination with azoles for fungal infections.